ReviewInternational journal of molecular sciences2021
Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- CARD14-Associated Papulosquamous Eruption (CAPE): An Updated Review of Pathogenesis and Treatment.International journal of dermatology · 2026Review
- IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.International journal of molecular sciences · 2026Review
- Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2026Review
- Dermal adipogenesis protects against neutrophilic skin inflammation during psoriasis pathogenesis.Cellular & molecular immunology · 2025Article
- Generalized Pustular Psoriasis Brazilian Experts Survey: Challenges in Disease Management.Dermatology and therapy · 2025Article
- Proteomic Profiling and Clinical Insights: The Role of MMP9 in Differentiating Psoriasis Vulgaris from Generalized Pustular Psoriasis.Journal of inflammation research · 2025Article
- Generalized Pustular Psoriasis During Early Pregnancy Successfully Treated with Spesolimab: A Case Report.International medical case reports journal · 2025Article
- Effectiveness and safety of spesolimab in treating generalized pustular psoriasis: A comparative analysis of randomized controlled trials.Indian journal of pharmacology · 2024Article
- RNA-binding proteins potentially regulate alternative splicing of immune/inflammatory-associated genes during the progression of generalized pustular psoriasis.Archives of dermatological research · 2024Article
- Generalized Pustular Psoriasis and Systemic Organ Dysfunctions.International journal of molecular sciences · 2024Review
- Dynamics of a network mediated by IL-36 and involved in the pathogenesis of psoriasis.Frontiers in network physiology · 2024Article
- Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis.Journal of inflammation research · 2024Article
- The Current Advancement in Psoriasis.Cureus · 2023Review
- Consideration of serum IL-36α and β levels trends in two patients with chikungunya fever.Clinical case reports · 2023Article
- Exploring the Clinical Features, Immunopathogenesis and Approach to Diagnosis for Generalized Pustular Psoriasis [Podcast].Clinical, cosmetic and investigational dermatology · 2023Article
- A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.Dermatology and therapy · 2022Review
- Review
- Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments.American journal of clinical dermatology · 2022Review
- Diagnosis of Generalized Pustular Psoriasis.American journal of clinical dermatology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized pustular psoriasis (GPP) is a severe, relapsing, immune-mediated disease characterized by the presence of multiple sterile pustules all over the body. The exact pathomechanisms behind GPP remain elusive, although increased interest in the genetic basis and immunological disturbances have provided some revealing insights into the underlying signaling pathways and their mutual interaction. The genetic background of GPP has been thoroughly investigated over the past few years. The conducted studies have identified genetic variants that predispose to pustular forms of psoriasis. The loss-of-function mutation of the interleukin 36 receptor antagonist gene, along with rare gain-of-function mutations in the gene that encodes the keratinocyte signaling molecule (CARD14), are examples of the uncovered abnormalities. Interleukin 36 (IL-36), along with neutrophils, is now considered a central cytokine in GPP pathogenesis, with IL-36 signaling providing a link between innate and adaptive immune responses. More recently, a new concept of inflammation, caused by a predominantly genetically determined abnormal activation of innate immune response and leading to inflammatory keratinization, has arisen. GPP is currently considered a representative of this novel group of skin conditions, called autoinflammatory keratinization diseases. As no therapeutic agents have been approved for GPP to date in the United States and Europe, the novel anti-IL-36R antibodies are particularly promising and may revolutionize management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.